Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value.
Frail Leukemia Patients See Better Results With New Blood Monitoring
This single-center retrospective analysis evaluated long-course venetoclax combined with hypomethylating agents in unfit AML patients. Resul…
A new look at blood tests shows how well frail leukemia patients respond to standard treatment.
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Case report of ATRA and VAH regimen in refractory EVI1-positive AML
New hope for tough AML cases
This case report with a brief literature review describes a 42-year-old patient with refractory EVI1-positive AML. The patient achieved comp…
A patient with high-risk AML and the tough EVI1 marker achieved complete remission after failing standard treatments, offering new hope for …
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS. The analysis pooled …
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…
Case report: obinutuzumab and venetoclax associated with nephrotic syndrome resolution in two CLL patients
Two CLL patients saw kidney condition improve after targeted cancer treatment
A case report describes two patients with chronic lymphocytic leukemia (CLL) and concomitant nephrotic syndrome. Both patients showed clinic…
Two CLL patients saw kidney problems improve after targeted cancer treatment, resolving symptoms and reducing urine protein within weeks.